A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Teva Pharmaceuticals USA
  • Most Recent Events

    • 26 Feb 2013 Secondary endpoint results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 09 Nov 2012 Results were presented at the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in November 2012.
    • 22 May 2012 Actual end date changed from Dec 2010 to Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top